Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression.

Rocha NM, Bulger DA, Frontini A, Titheradge H, Gribsholt SB, Knox R, Page M, Harris J, Payne F, Adams C, Sleigh A, Crawford J, Gjesing AP, Bork-Jensen J, Pedersen O, Barroso I, Hansen T, Cox H, Reilly M, Rossor A, Brown RJ, Taylor SI, McHale D, Armstrong M, Oral EA, Saudek V, O'Rahilly SI, Maher ER, Richelsen B, Savage DB, Semple RK.

Elife. 2017 Apr 17;6. pii: e23813. doi: 10.7554/eLife.23813. [Epub ahead of print]

2.

Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.

Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, DiPaola F, Chenevert TL, Horowitz JF, Buggs-Saxton C, Rupani AR, Thomas PE, Tayeh MK, Innis JW, Omary MB, Conjeevaram H, Oral EA.

Clin Endocrinol (Oxf). 2017 May;86(5):698-707. doi: 10.1111/cen.13311. Epub 2017 Mar 27.

PMID:
28199729
3.

Milestone Weight Loss Goals (Weight Normalization and Remission of Obesity) after Gastric Bypass Surgery: Long-Term Results from the University of Michigan.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, Bellers D, Lockwood AL, Varban OA, Oral EA.

Obes Surg. 2017 Jan 13. doi: 10.1007/s11695-016-2533-1. [Epub ahead of print]

PMID:
28084587
4.

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T.

J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. Epub 2016 Oct 6.

5.

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Oral EA.

Drugs Context. 2016 Sep 2;5:212299. doi: 10.7573/dic.212299. eCollection 2016. Review.

6.

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.

J Diabetes Metab. 2016 Mar;7(3). pii: 659. Epub 2016 Mar 23.

7.

Roux-En-Y Gastric Bypass Vs. Sleeve Gastrectomy: Balancing the Risks of Surgery with the Benefits of Weight Loss.

Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, Nay CK, Lockwood AL, Varban OA, Oral EA.

Obes Surg. 2017 Jan;27(1):154-161. doi: 10.1007/s11695-016-2265-2.

8.

Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome.

Walden P, Jiang Q, Jackson EA, Oral EA, Weintraub MS, Rubenfire M.

Diabetes Metab Syndr Obes. 2016 Jun 1;9:177-84. doi: 10.2147/DMSO.S94772. eCollection 2016.

9.

Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.

Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.

Clin Endocrinol (Oxf). 2016 Jul;85(1):137-49. doi: 10.1111/cen.12980. Epub 2016 Feb 2.

PMID:
26589105
10.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group..

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

11.

A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.

Lebastchi J, Ajluni N, Neidert A, Oral EA.

J Clin Endocrinol Metab. 2015 Nov;100(11):3967-70. doi: 10.1210/jc.2015-2589. Epub 2015 Sep 21.

12.

A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis.

Reilly SM, Ahmadian M, Zamarron BF, Chang L, Uhm M, Poirier B, Peng X, Krause DM, Korytnaya E, Neidert A, Liddle C, Yu RT, Lumeng CN, Oral EA, Downes M, Evans RM, Saltiel AR.

Nat Commun. 2015 Jan 12;6:6047. doi: 10.1038/ncomms7047.

13.

Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact.

Subauste AR, Esfandiari NH, Qu Y, Oral EA, Aaronson KD, Pagani FD, Gianchandani RG.

Hosp Pract (1995). 2014 Aug;42(3):116-22. doi: 10.3810/hp.2014.08.1124.

PMID:
25255413
14.

Hemodynamic, autonomic, and vascular effects of exposure to coarse particulate matter air pollution from a rural location.

Brook RD, Bard RL, Morishita M, Dvonch JT, Wang L, Yang HY, Spino C, Mukherjee B, Kaplan MJ, Yalavarthi S, Oral EA, Ajluni N, Sun Q, Brook JR, Harkema J, Rajagopalan S.

Environ Health Perspect. 2014 Jun;122(6):624-30. doi: 10.1289/ehp.1306595. Epub 2014 Mar 11.

15.

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group..

Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. doi: 10.1002/acr.22212.

16.

The effect of acute exposure to coarse particulate matter air pollution in a rural location on circulating endothelial progenitor cells: results from a randomized controlled study.

Brook RD, Bard RL, Kaplan MJ, Yalavarthi S, Morishita M, Dvonch JT, Wang L, Yang HY, Spino C, Mukherjee B, Oral EA, Sun Q, Brook JR, Harkema J, Rajagopalan S.

Inhal Toxicol. 2013 Aug;25(10):587-92. doi: 10.3109/08958378.2013.814733. Epub 2013 Aug 6.

17.

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group..

Medicine (Baltimore). 2013 Jul;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9.

18.

Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group..

Arthritis Rheum. 2013 Jul;65(7):1934-41. doi: 10.1002/art.37985.

19.

The clinical approach to the detection of lipodystrophy - an AACE consensus statement.

Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C; American Association of Clinical Endocrinologists..

Endocr Pract. 2013 Jan-Feb;19(1):107-16. No abstract available.

20.

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group..

Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d.

Supplemental Content

Loading ...
Support Center